Form 10-Q October 31, 2017
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER: 814-00802

HORIZON TECHNOLOGY FINANCE CORPORATION

(Exact name of registrant as specified in its charter)

Horizon Technology Finance Corp

DELAWARE (State or other jurisdiction of incorporation or c	27-2114934 <i>(I.R.S. Employalist)</i>	yer Identification No.)	
312 Farmington Avenue Farmington, CT (Address of principal executive offices)	06032 (Zip Code)		
(860) 676-8654 (Registrant's telephone number, including ar	rea code)		
Indicate by check mark whether the registrant (1 Securities Exchange Act of 1934 during the precrequired to file such reports), and (2) has been so	ceding 12 months (or for such	shorter period that the	registrant was
Indicate by check mark whether the registrant has any, every Interactive Data File required to be so 232.405 of this chapter) during the preceding 12 submit and post such files). Yes "No"	submitted and posted pursuant	to Rule 405 of Regulat	ion S-T (§
Indicate by check mark whether the registrant is filer, smaller reporting company, or an emerging "accelerated filer," "smaller reporting company,	g growth company. See the de	efinitions of "large acce	lerated filer,"
Large accelerated filer "		Accelerated filer	X
Non-accelerated filer " (Do not check if a	a smaller reporting company)	Smaller reporting com	pany"
Emerging growth company "			
If an emerging growth company, indicate by che transition period for complying with any new or 13(a) of the Exchange Act	•		

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No x

The number of shares of the registrant's common stock, \$0.001 par value per share, outstanding as of October 31, 2017 was 11,517,984.

HORIZON TECHNOLOGY FINANCE CORPORATION

FORM 10-Q

TABLE OF CONTENTS

	DADÆ I	Page
Item 1.	PART I Consolidated Financial Statements	<u>3</u>
	Consolidated Statements of Assets and Liabilities as of September 30, 2017 and December 31, 2016 (unaudited)	<u>3</u>
	Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (unaudited)	<u>4</u>
	Consolidated Statements of Changes in Net Assets for the nine months ended September 30, 2017 and 2016 (unaudited)	<u>5</u>
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016 (unaudited)	<u>6</u>
	Consolidated Schedules of Investments as of September 30, 2017 and December 31, 2016 (unaudited) Notes to the Consolidated Financial Statements (unaudited)	<u>7</u> <u>18</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations Operations and Operations Disclaration Disclaration Disclaration Disclaration Disclaration Disclaration Discussion and Disclaration Disclaration Discussion and Disclaration Discussion and Disclaration Discussion and Dis	<u>38</u>
<u>Item 3.</u> <u>Item 4.</u>	Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures	<u>52</u> <u>53</u>
	PART II	
	<u>Legal Proceedings</u>	<u>54</u>
	Risk Factors	<u>54</u>
Item 2. Item 3.	Unregistered Sales of Equity Securities and Use of Proceeds Defaults Upon Senior Securities	 54 54 54 54 54 54 55
<u>Item 4.</u>	Mine Safety Disclosures	<u>54</u> 54
	Other Information	54
Item 6.	<u>Exhibits</u>	<u>54</u>
	<u>Signatures</u>	<u>55</u>
EX-31.1		
EX-31.2		
EX-32.1		
EX-32.2		

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Assets and Liabilities (Unaudited)

(Dollars in thousands, except share and per share data)

	September 30, 2017	December 31, 2016
Assets		
Non-affiliate investments at fair value (cost of \$184,124 and \$211,627, respectively) (Note 4)	\$ 173,211	\$ 194,003
Affiliate investments at fair value (cost of \$3,767)(Note 5)	3,493	_
Total investments at fair value (cost of \$187,891 and \$211,627, respectively) Cash	176,704 22,326	194,003 37,135
Interest receivable	4,366	6,036
Other assets	1,413	2,078
Total assets	204,809	\$ 239,252
Liabilities		
Borrowings (Note 7)	\$ 64,101	\$ 95,597
Distributions payable	3,455	3,453
Base management fee payable (Note 3)	304	337
Incentive fee payable (Note 3)	258	_
Other accrued expenses	695	673
Total liabilities	68,813	100,060
Commitments and Contingencies (Note 8)		
Net assets		
Preferred stock, par value \$0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2017 and December 31, 2016	_	_
Common stock, par value \$0.001 per share, 100,000,000 shares authorized, 11,684,244 and 11,671,966 shares issued and 11,516,779 and 11,510,424 shares	12	12

outstanding as of September 30, 2017 and December 31, 2016, respectively Paid-in capital in excess of par 179,626 179,551 Distributions in excess of net investment income (846 (397) Net unrealized depreciation on investments (11,187 (19,463) Net realized loss on investments (20,511 (31,609) Total net assets 135,996 139,192 Total liabilities and net assets \$ 204,809 \$ 239,252 Net asset value per common share \$ 11.81 \$ 12.09

See Notes to Consolidated Financial Statements

Consolidated Statements of Operations (Unaudited)

(Dollars in thousands, except share and per share data)

	For the The September 2017	ree Months Ended 30, 2016	For the Nir September 2017	ne Months Ended 30, 2016	d
Investment income	2017	2010	2017	2010	
Interest income on investments					
Interest income on non-affiliate investments	\$6,164	\$6,819	\$17,861	\$24,610	
Interest income on affiliate investments	81	\$0,019	81	\$24,010	
Total interest income on investments	6,245		17,942	<u> </u>	
Fee income	0,243	0,019	17,942	24,010	
Prepayment fee income on non-affiliate investments	399	355	1,187	618	
Fee income on non-affiliate investments	130	434	485	769	
Total investment income	6,774	7,608	19,614	25,997	
Expenses	0,774	7,000	17,014	23,771	
Interest expense	1,140	1,420	3,540	4,466	
Base management fee (Note 3)	921	1,135	2,783	3,666	
Performance based incentive fee (Note 3)	258	1,133	1,094	2,126	
Administrative fee (Note 3)	194	<u> </u>	575	753	
Professional fees	275	315	1,105	1,159	
General and administrative	189	218	600	681	
Total expenses	2,977	3,285	9,697	12,851	
Net investment income before excise tax	3,797	4,323	9,097	13,146	
Credit for excise tax	3,191	·) —	(138)
Net investment income	 3,797	4,375	9,917	13,284	,
Net investment income	3,191	4,373	9,917	13,204	
Net realized and unrealized loss on investments					
Net realized (loss) gain on non-affiliate investments	(429) 5	(11,098) (2,857)
Net realized (loss) gain on investments	(429) 5	(11,098) (2,857)
Net unrealized (depreciation) appreciation on		,		, , ,	
non-affiliate investments	(640) (10,023) 8,295	(14,752)
Net unrealized depreciation on affiliate investments	(19) —	(19) —	
Net unrealized (depreciation) appreciation on	(659) (10,023) 8,276	(14.752	`
investments	(639) (10,023) 8,276	(14,752)
Net realized and unrealized loss on investments	(1,088) (10,018) (2,822) (17,609)
Net increase (decrease) in net assets resulting from operations	\$2,709	\$(5,643) \$7,095	\$(4,325)
Net investment income per common share	\$0.33	\$0.38	\$0.86	\$1.15	

Net increase (decrease) in net assets per common share	\$0.24	\$(0.49) \$0.62	\$(0.37))
Distributions declared per share	\$0.30	\$0.345	\$0.90	\$1.035	
Weighted average shares outstanding	11,518,552	11,549,508	11,516,246	11,543,995	

See Notes to Consolidated Financial Statements

Consolidated Statements of Changes in Net Assets (Unaudited)

(Dollars in thousands, except share data)

	Common Sto		Paid-In Capital in Excess of	Distribution in Excess of Net Investment	Unrealized Depreciation	Loss on	Total Net
Dalamas at Dagamban 21	Shares	Amoun	tPar	Income	Investments	Investment	ts Assets
Balance at December 31, 2015	11,535,212	\$ 12	\$179,707	\$ (2,006) \$ (5,227) \$ (12,735) \$159,751
Net decrease in net assets resulting from operations, net of excise tax	_	_	_	13,284	(14,752) (2,857) (4,325)
Issuance of common stock under dividend reinvestment plan	18,048	_	211	_	_	_	211
Repurchases of common stock	(1,319)	_	(16)				(16)
Distributions declared			_	(11,952) —	_	(11,952)
Balance at September 30, 2016	11,551,941	\$ 12	\$179,902	\$ (674) \$ (19,979) \$ (15,592) \$143,669
Balance at December 31, 2016 Net increase in net assets	11,510,424	\$ 12	\$179,551	\$ (397) \$ (19,463) \$ (20,511) \$139,192
resulting from operations, net of excise tax	_	_	_	9,917	8,276	(11,098) 7,095
Issuance of common stock under dividend reinvestment plan	12,278	_	134	_	_	_	134
Repurchases of common stock	(5,923)	_	(59)	_	_	_	(59)
Distributions declared	_			(10,366) —		(10,366)
Balance at September 30, 2017	11,516,779	\$ 12	\$179,626	\$ (846) \$ (11,187) \$ (31,609) \$135,996

See Notes to Consolidated Financial Statements

Consolidated Statements of Cash Flows (Unaudited)

	For the Nin September 2017	30,	onths Ende	d
Cash flows from operating activities:				
Net increase (decrease) in net assets resulting from operations	\$ 7,095		\$ (4,325)
Adjustments to reconcile net increase (decrease) in net assets resulting from operations				
to net cash provided by operating activities:				
Amortization of debt issuance costs	383		434	
Net realized loss on investments	11,098		2,857	
Net unrealized (appreciation) depreciation on investments	(8,276)	14,752	
Purchase of investments	(66,311)	(45,223)
Principal payments received on investments	80,062		69,266	
Proceeds from sale of investments	1,572		939	
Changes in assets and liabilities:				
Net decrease in investments in money market funds			285	
Net decrease in restricted investments in money market funds			1,091	
Decrease (increase) in interest receivable	253		(1,749)
Decrease in end-of-term payments	1,008		200	
Decrease in unearned income	(437)	(476)
Decrease in other assets	423		143	
Increase (decrease) in other accrued expenses	22		(220)
Decrease in base management fee payable	(33)	(22)
Increase (decrease) in incentive fee payable	258		(1,028)
Net cash provided by operating activities	27,117		36,924	
Cash flows from financing activities:				
Proceeds from issuance of 2022 Notes	32,500			
Repayment of Asset-Backed Notes			(14,546)
Advances on credit facility	34,000		10,000	
Repayment of credit facility	(97,000)	(15,000)
Distributions paid	(10,230)	(11,736)
Repurchase of common stock	(59)	(16)
Debt issuance costs	(1,137)	(221)
Net cash used in financing activities	(41,926)	(31,519)
Net (decrease) increase in cash	(14,809)	5,405	
Cash:		,	•	
Beginning of period	37,135		20,765	
End of period	\$ 22,326		\$ 26,170	

Supplemental disclosure of cash flow information:

TT		
Cash paid for interest	\$ 3,242	\$ 4,051
Supplemental non-cash investing and financing activities:		
Warrant investments received and recorded as unearned income	\$ 1,482	\$ 446
Distributions payable	\$ 3,455	\$ 3,985
End-of-term payments receivable	\$ 3,657	\$ 4,859

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2017

Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Principal Amount	Investments	Fair Value
Non-Affiliate Investmen	ats — 127.3% (8)			(6)	
Non-Affiliate Debt Inve Non-Affiliate Debt Inve	· ·	. ,			
Palatin Technologies, Inc. (2)(5)	Biotechnology	Term Loan (9.73% cash (Libor + 8.50%; Floor	\$ 2,500	\$ 2,475	\$2,475
		9.00%), 5.00% ETP, Due 1/1/19) Term Loan (9.73% cash (Libor + 8.50%; Floor	3,667	3,635	3,635
Sample6, Inc. (2)	Biotechnology	9.00%), 5.00% ETP, Due 8/1/19) Term Loan (10.23% cash (Libor + 9.00%; Floor	551	548	548
		9.50%; Ceiling 11.00%), 4.50% ETP, Due 8/1/18) Term Loan (10.23% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.50% ETP,	335	332	332
		Due 8/1/18) Term Loan (10.23% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.50% ETP,	1,181	1,172	1,172
vTv Therapeutics Inc. (2)(5)	Biotechnology	Due 8/1/18) Term Loan (11.23% cash (Libor + 10.00%; Floor	6,250	6,191	6,191
		10.50%), 6.00% ETP, Due 5/1/20) Term Loan (11.23% cash (Libor + 10.00%; Floor	3,750	3,696	3,696
Titan Pharmaceuticals, Inc. (2)(5)	Drug Delivery	10.50%), 6.00% ETP, Due 10/1/20) Term Loan (9.63% cash (Libor + 8.40%; Floor	3,500	3,394	3,394
		9.50%), 5.00% ETP, Due 6/1/21) Term Loan (9.63% cash (Libor + 8.40%; Floor	3,500	3,425	3,425

	3 9	37			
Lantos Technologies, Inc. (2)	Medical Device	9.50%), 5.00% ETP, Due 6/1/21) Term Loan (11.73% cash (Libor + 10.50%; Floor 11.50%), 8.91% ETP, Due 5/1/19)	2,479	2,465	2,183
Mederi Therapeutics, Inc. (2)	Medical Device	Term Loan (12.87% cash (Libor + 11.82%; Floor	173	171	171
		12.00%), 6.00% ETP, Due 12/1/17) Term Loan (12.87% cash (Libor + 11.82%; Floor 12.00%), 6.00% ETP, Due 12/1/17)	173	171	171
NinePoint Medical, Inc. (2)	Medical Device	Term Loan (9.98% cash (Libor + 8.75%; Floor 9.25%), 4.50% ETP, Due 3/1/19)	3,000	2,975	2,975
		Term Loan (9.98% cash (Libor + 8.75%; Floor 9.25%), 4.50% ETP, Due 3/1/19)	1,500	1,484	1,484
Total Non-Affiliate Debt Non-Affiliate Debt Inves		e Science		32,134	31,852
PebblePost, Inc. (2)	Communications	Term Loan (10.49% cash (Libor + 9.26%; Floor 10.25%), 4.00% ETP, Due 7/1/21)	4,000	3,869	3,869
		Term Loan (10.49% cash (Libor + 9.26%; Floor	4,000	3,928	3,928
Gwynnie Bee, Inc. (2)	Consumer-related Technologies	10.25%), 4.00% ETP, Due 7/1/21) Term Loan (11.74% cash (Libor + 10.50%; Floor	67	66	66
		11.00%; Ceiling 12.50%), 2.00% ETP, Due 11/1/17) Term Loan (11.74% cash (Libor + 10.50%; Floor 11.00%; Ceiling 12.50%), 2.00%	133	130	130
		ETP, Due 2/1/18) Term Loan (11.74% cash (Libor + 10.50%; Floor 11.00%; Ceiling 12.50%), 2.00% ETP, Due 4/1/18)	200	197	197
Le Tote, Inc. (2)	Consumer-related Technologies	Term Loan (10.88% cash (Libor + 9.65%; Floor	4,000	3,955	3,955
		10.15%), 5.00% ETP, Due 3/1/20) Term Loan (10.88% cash (Libor + 9.65%; Floor	3,000	2,966	2,966
Rhapsody International, Inc. (2)	Consumer-related Technologies	10.15%), 5.00% ETP, Due 3/1/20) Term Loan (11.73% cash (Libor + 10.50%; Floor	6,000	5,881	5,881
SavingStar, Inc. (2)	Consumer-related Technologies	11.00%), 3.00% ETP, Due 10/1/19) Term Loan (11.63% cash (Libor + 10.40%; Floor	2,267	2,237	2,237
		10.90%), 4.25% ETP, Due 6/1/20) Term Loan (11.63% cash (Libor + 10.40%; Floor 10.90%), 3.80% ETP, Due 11/1/20)	1,978	1,911	1,911

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

IgnitionOne, Inc. (2)	Internet and Media	Term Loan (11.46% cash (Libor + 10.23%; Floor 10.23%), 2.00% ETP, Due 4/1/22)	3,000	2,822	2,822
		Term Loan (11.46% cash (Libor + 10.23%; Floor 10.23%), 2.00% ETP, Due 4/1/22)	3,000	2,822	2,822
		Term Loan (11.46% cash (Libor + 10.23%; Floor 10.23%), 2.00% ETP, Due 4/1/22)	3,000	2,822	2,822
		Term Loan (11.46% cash (Libor + 10.23%; Floor	3,000	2,822	2,822
Jump Ramp Games, Inc. (2)	Internet and Media	10.23%), 2.00% ETP, Due 4/1/22) Term Loan (10.96% cash (Libor + 9.73%), 3.00% ETP, Due 4/1/21)	4,000	3,937	3,937
Kixeye, Inc. (2)	Internet and Media	Term Loan (10.83% cash (Libor + 9.60%; Floor	3,000	2,896	2,896
		10.75%), 2.00% ETP, Due 9/1/21) Term Loan (10.83% cash (Libor + 9.60%; Floor 10.75%), 2.00% ETP, Due 9/1/21)	3,000	2,941	2,941

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2017

			Principal		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount	Investments (6)	Value
MediaBrix, Inc. (2)	Internet and Media	Term Loan (12.23% cash (Libor + 11.00%; Floor	4,000	3,974	3,974
Rocket Lawyer Incorporated (2)	Internet and Media	11.50%), 3.00% ETP, Due 1/1/20) Term Loan (10.63% cash (Libor + 9.40%; Floor 10.50%), 3.00% ETP, Due 7/1/21)	4,000	3,899	3,899
		Term Loan (10.63% cash (Libor + 9.40%; Floor	4,000	3,928	3,928
Zinio Holdings, LLC (2)	Internet and Media	10.50%), 3.00% ETP, Due 7/1/21) Term Loan (12.48% cash (Libor + 11.25%; Floor	4,000	3,975	3,975
The NanoSteel Company, Inc. (2)	Materials	11.75%), 5.00% ETP, Due 2/1/20) Term Loan (10.73% cash (Libor + 9.50%; Floor	4,792	4,708	4,708
		10.00%), 7.20% ETP, Due 1/1/20) Term Loan (10.73% cash (Libor + 9.50%; Floor	2,396	2,354	2,354
		10.00%), 6.45% ETP, Due 1/1/20) Term Loan (10.73% cash (Libor + 9.50%; Floor	2,500	2,452	2,452
Powerhouse Dynamics, Inc. (2)	Power Management	10.00%), 5.85% ETP, Due 3/1/20) Term Loan (11.93% cash (Libor + 10.70%; Floor	1,500	1,480	1,480
Luxtera, Inc.	Semiconductors	11.20%), 3.00% ETP, Due 3/1/19) Term Loan (11.00% cash (Prime + 6.75%),	2,000	1,891	1,891
		Due 3/28/20) Term Loan (11.00% cash (Prime + 6.75%),	1,500	1,437	1,437
Bridge2 Solutions, Inc. (2)	Software	Due 3/28/20) Term Loan (12.23% cash (Libor + 11.00%; Floor	2,933	2,916	2,916

	3 3	37			
		11.50%; Ceiling 14.50%), 2.00% ETP, Due 7/1/19) Term Loan 12.23% cash (Libor +			
		11.00%; Floor 11.50%; Ceiling 14.50%), 2.00% ETP, Due 1/1/20)	933	931	931
Digital Signal Corporation (11)(13)	Software	Term Loan (11.48% cash (Libor + 10.25%; Floor 10.43%), 5.00% ETP, Due 7/1/19)	1,285	1,252	965
		Term Loan (11.48% cash (Libor + 10.25%; Floor 10.43%), 5.00% ETP, Due 7/1/19)	1,285	1,252	965
		Term Loan (10.00% cash, Due 12/31/17)	350	350	270
Education Elements, Inc. (2)	Software	Term Loan (11.23% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 1/1/19)	1,000	986	986
		Term Loan (11.23% cash (Libor + 10.00%; Floor	1,100	1,085	1,085
Netuitive, Inc.	Software	10.50%), 4.00% ETP, Due 8/1/19) Term Loan (13.48% cash (Libor + 12.25%; Floor 12.50%), 3.33% ETP, Due 9/1/18)	214	230	230
ScoreBig, Inc. (2)(11)(12)	Software	Term Loan (11.08% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 4/1/19)	3,403	3,332	945
		Term Loan (11.23% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 4/1/19)	3,403	3,360	953
		Term Loan (11.23% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 3/1/20)	2,000	1,950	553
		Term Loan (11.23% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 10/31/16)	203	203	58
		Term Loan (11.23% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 11/11/19)	324	324	91
ShopKeep.com, Inc. (2)	Software	Term Loan (11.18% cash (Libor + 9.95%; Floor 10.45%), 3.00% ETP, Due 4/1/20)	6,000	5,915	5,915
		Term Loan (11.18% cash (Libor + 9.95%; Floor	4,000	3,934	3,934
SIGNiX, Inc.	Software	10.45%), 3.00% ETP, Due 9/1/20) Term Loan (12.23% cash (Libor + 11.00%; Floor 11.50%), 3.5% ETP, Due 4/1/19)	2,200	2,094	1,899
SilkRoad Technology, Inc. (2)	Software	Term Loan (11.58% cash (Libor + 10.35%; Floor 10.85%; Ceiling 12.85%), 5.00% ETP,	7,000	6,894	6,894
		Due 6/1/20)			

Weblinc Corporation (2)	Software	Term Loan (11.48% cash (Libor +	3,000	2,909	2,909
webline Corporation (2)	Software	10.25%; Floor	3,000	2,909	2,909
		11.25%), 3.00% ETP, Due 3/1/21)			
xTech Holdings, Inc. (2)	Software	Term Loan (11.73% cash (Libor +	1,056	1,042	1,042
x recti Holdings, file. (2)	Software	10.50%; Floor	1,030	1,042	1,042
		11.00%), 3.00% ETP, Due 4/1/19)			
		Term Loan (11.73% cash (Libor +	1 667	1 644	1 6 4 4
		10.50%; Floor	1,667	1,644	1,644
		11.00%), 3.00% ETP, Due 3/1/20)			
Total Non-Affiliate Debt Investments — Technology					111,485

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2017

(Dollars in thousands)

Argos Therapeutics, Inc. (2)(5)

Ocera Therapeutics, Inc. (2)(5)

Revance Therapeutics, Inc. (5)

Palatin Technologies, Inc. (2)(5)

Inotek Pharmaceuticals Corporation (5) Biotechnology

Celsion Corporation (5)

Sample6, Inc. (2)

Portfolio Company (1)	Sector	Type of Investment $(3)(4)(7)(9)(10)$
Non-Affiliate Debt Investments — Clea	antech — 4.4% (8)	
Lehigh Technologies, Inc. (2)	Waste Recycling	Term Loan (10.95% cash (Libor + 9.72%), 1.67% E Due 8/1/19)
		Term Loan (10.95% cash (Libor + 9.72%), 1.67% E
		Due 8/1/19)
Total Non-Affiliate Debt Investments –	Cleantech	
Non-Affiliate Debt Investments — Hea	lthcare information and services -	- 6.3% (8)
Interleukin Genetics, Inc. (2)(5)(11)	Diagnostics	Term Loan (11.73% cash (Libor + 10.50%;
		Floor 11.00%), 6.50% ETP, Due 10/1/18)
		Term Loan (8.00% PIK, Due 1/1/22) (15)
Watermark Medical, Inc. (2)	Other Healthcare	Term Loan (10.73% cash (Libor + 9.50%; Floor 10.
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
		Term Loan (10.73% cash (Libor + 9.50%; Floor 10.
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
		Term Loan (10.73% cash (Libor + 9.50%; Floor 10.
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)
HealthEdge Software, Inc. (2)	Software	Term Loan (9.48% cash (Libor + 8.25%;
		Floor 9.25%), 3.00% ETP, Due 7/1/22)
Total Non-Affiliate Debt Investments –	 Healthcare information and ser 	vices
Total Non- Affiliate Debt Investments		
Non-Affiliate Warrant Investments — 5	5.9% (8)	
Non-Affiliate Warrants — Life Science		
ACT Biotech Corporation	Biotechnology	1,521,820 Preferred Stock Warrants
Alpine Immune Sciences, Inc. (5)	Biotechnology	4,634 Common Stock Warrants

Biotechnology

Biotechnology

Biotechnology

Biotechnology

Biotechnology

Biotechnology

73,112 Common Stock Warrants

28,204 Common Stock Warrants

6,491 Common Stock Warrants

608,058 Common Stock Warrants

34,113 Common Stock Warrants

661,956 Preferred Stock Warrants

408 Common Stock Warrants

Strongbridge U.S. Inc. (5)	Biotechnology	160,714 Common Stock Warrants
Sunesis Pharmaceuticals, Inc. (5)	Biotechnology	2,050 Common Stock Warrants
vTv Therapeutics Inc. (2)(5)	Biotechnology	93,896 Common Stock Warrants
Titan Pharmaceuticals, Inc. (2)(5)	Drug Delivery	280,612 Common Stock Warrants
AccuVein Inc. (2)	Medical Device	75,769 Preferred Stock Warrants
EnteroMedics, Inc. (5)	Medical Device	134 Common Stock Warrants
IntegenX, Inc. (2)	Medical Device	170,646 Preferred Stock Warrants
Lantos Technologies, Inc. (2)	Medical Device	2,763,646 Preferred Stock Warrants
Mederi Therapeutics, Inc. (2)	Medical Device	248,736 Preferred Stock Warrants
Mitralign, Inc. (2)	Medical Device	641,909 Preferred Stock Warrants
NinePoint Medical, Inc. (2)	Medical Device	566,037 Preferred Stock Warrants
OraMetrix, Inc. (2)	Medical Device	812,348 Preferred Stock Warrants
Tryton Medical, Inc. (2)	Medical Device	122,362 Preferred Stock Warrants
ViOptix, Inc.	Medical Device	375,763 Preferred Stock Warrants
Total Non-Affiliate Warrants — Life Sc	ience	
Non-Affiliate Warrants — Technology -	— 4.2% (8)	
Ekahau, Inc. (2)	Communications	978,261 Preferred Stock Warrants
PebblePost, Inc. (2)	Communications	598,580 Preferred Stock Warrants
Additech, Inc. (2)	Consumer-related Technologies	150,000 Preferred Stock Warrants
Gwynnie Bee, Inc. (2)	Consumer-related Technologies	268,591 Preferred Stock Warrants
Le Tote, Inc. (2)	Consumer-related Technologies	202,974 Preferred Stock Warrants
Rhapsody International Inc. (2)	Consumer-related Technologies	852,273 Common Stock Warrants
SavingStar, Inc. (2)	Consumer-related Technologies	850,439 Preferred Stock Warrants
XIOtech, Inc.	Data Storage	96 Preferred Stock Warrants
IgnitionOne, Inc. (2)	Internet and Media	262,910 Preferred Stock Warrants
Jump Ramp Games, Inc. (2)	Internet and Media	159,766 Preferred Stock Warrants
Kixeye, Inc. (2)	Internet and Media	530,751 Preferred Stock Warrants
Rocket Lawyer Incorporated (2)	Internet and Media	235,549 Preferred Stock Warrants
The NanoSteel Company, Inc. (2)	Materials	379,360 Preferred Stock Warrants
IntelePeer, Inc.	Networking	141,549 Common Stock Warrants
Nanocomp Technologies, Inc. (2)	Networking	1,414,921 Preferred Stock Warrants
Powerhouse Dynamics, Inc. (2)	Power Management	290,698 Preferred Stock Warrants

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2017

Portfolio Company (1)	Sector	Type of Investment $(3)(4)(7)(9)(10)$
Avalanche Technology, Inc. (2)	Semiconductors	202,602 Preferred Stock Warrants
eASIC Corporation (2)	Semiconductors	40,445 Preferred Stock Warrants
Kaminario, Inc.	Semiconductors	1,087,203 Preferred Stock Warrants
Luxtera, Inc.(2)	Semiconductors	3,546,553 Preferred Stock Warrants
Soraa, Inc. (2)	Semiconductors	203,616 Preferred Stock Warrants
Bolt Solutions Inc. (2)	Software	202,892 Preferred Stock Warrants
Bridge2 Solutions, Inc. (2)	Software	75,458 Common Stock Warrants
Clarabridge, Inc.	Software	53,486 Preferred Stock Warrants
Digital Signal Corporation	Software	125,116 Common Stock Warrants
Education Elements, Inc. (2)	Software	238,121 Preferred Stock Warrants
Lotame Solutions, Inc. (2)	Software	288,115 Preferred Stock Warrants
Netuitive, Inc.	Software	41,569 Common Stock Warrants
Riv Data Corp. (2)	Software	321,428 Preferred Stock Warrants
ShopKeep.com, Inc. (2)	Software	165,779 Preferred Stock Warrants
SIGNiX, Inc.	Software	114,767 Preferred Stock Warrants
Skyword, Inc.	Software	301,056 Preferred Stock Warrants
SpringCM, Inc. (2)	Software	2,385,686 Preferred Stock Warrants
Sys-Tech Solutions, Inc.	Software	375,000 Preferred Stock Warrants
Visage Mobile, Inc.	Software	1,692,047 Preferred Stock Warrants
Weblinc Corporation (2)	Software	195,122 Preferred Stock Warrants
xTech Holdings, Inc. (2)	Software	158,730 Preferred Stock Warrants
Total Non-Affiliate Warrants — Technol	logy	
Non-Affiliate Warrants — Cleantech —	0.1% (8)	
Renmatix, Inc.	Alternative Energy	53,022 Preferred Stock Warrants
Rypos, Inc. (2)	Energy Efficiency	5,627 Preferred Stock Warrants
Tigo Energy, Inc. (2)	Energy Efficiency	804,604 Preferred Stock Warrants
Total Non-Affiliate Warrants — Cleante		
Non-Affiliate Warrants — Healthcare in	•	8)
Interleukin Genetics, Inc. (2)(5)	Diagnostics	12,452,290 Common Stock Warrants
LifePrint Group, Inc. (2)	Diagnostics	49,000 Preferred Stock Warrants
ProterixBio, Inc. (2)	Diagnostics	3,156 Common Stock Warrants
Singulex, Inc.	Other Healthcare	294,231 Preferred Stock Warrants

Verity Solutions Group, Inc.Other Healthcare300,360 Preferred Stock WarrantsWatermark Medical, Inc. (2)Other Healthcare27,373 Preferred Stock WarrantsHealthEdge Software, Inc. (2)Software63,291 Preferred Stock WarrantsMedsphere Systems Corporation (2)Software7,097,792 Preferred Stock WarrantsRecondo Technology, Inc. (2)Software556,796 Preferred Stock Warrants

Total Non-Affiliate Warrants — Healthcare information and services

Total Non-Affiliate Warrants

Non-Affiliate Other Investments — 4.3% (8)

Espero Pharmaceuticals, Inc. (14) Biotechnology Royalty Agreement ZetrOZ, Inc. Medical Device Royalty Agreement

Vette Technology, LLC Data Storage Royalty Agreement Due 4/18/2019

Total Non-Affiliate Other Investments

Non-Affiliate Equity — 1.0% (8)

Insmed Incorporated (5)Biotechnology33,208 Common StockRevance Therapeutics, Inc.(5)Biotechnology5,125 Common StockSunesis Pharmaceuticals, Inc. (5)Biotechnology13,082 Common StockSnagAJob.com, Inc.Consumer-related Technologies82,974 Common Stock

Total Non-Affiliate Equity

Total Non-Affiliate Portfolio Investment Assets

Affiliate Investments — 2.6% (8)

Affiliate Debt Investments — Technology — 2.5% (8) Decisyon, Inc. Software

Term Loan (13.538% cash (Libor + 12.308%; Floo

12.50%), 8.00% ETP, Due 12/1/19)

Term Loan (13.538% cash (Libor + 12.308%; Floo

12.50%), 8.00% ETP, Due 12/1/19)

Term Loan (12.02% PIK , Due 4/15/19) (15) Term Loan (12.03% PIK , Due 4/15/19) (15)

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2017

		Principal	Cost of	Fair
Portfolio Company (1) Sector	Type of Investment (3)(4)(7)(9)(10)	Amount	Investments (6)	Value
	Term Loan (12.24% PIK, Due 4/15/19) (15)	750	750	714
Total Affiliate Debt Investments	3,536	3,368		
Affiliate Warrants — Technology	y - 0.0% (8)			
	82,967 Common Stock Warrants		46	
Total Affiliate Warrants —			46	_
Technology			-	
Affiliate Equity — Technology –	-0.1% (8)			
Decisyon, Inc. Software	45,365,936 Common Stock		185	125
Total Affiliate Equity			185	125
Total Affiliate Portfolio Investme	ent Assets		\$ 3,767	\$3,493
Total Portfolio Investment Assets	s - 129.9%(8)		\$ 187,891	\$176,704

- All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.
- (2) Has been pledged as collateral under the Key Facility.
- All non-affiliate investments are investments in which the Company owns less than 5% ownership of the voting (3) securities of the portfolio company. All affiliate investments are investments in which the Company owns 5% or
- more of the voting securities of the portfolio company.
- (4) All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company's debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments ("ETPs") and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at fixed rates for the term of the debt investment,

unless otherwise indicated. All debt investments based on LIBOR are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of September 30, 2017 is provided.

- (5) Portfolio company is a public company.
- (6) For debt investments, represents principal balance less unearned income.
- (7) Warrants, Equity and Other Investments are non-income producing.
- (8) Value as a percent of net assets.
- The Company did not have any non-qualifying assets under Section 55(a) of the Investment Company Act of 1940, as amended (the "1940 Act"), as of September 30, 2017. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets.
 - ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt
- (10) investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.
- (11) Debt investment is on non-accrual status at September 30, 2017.
 - ScoreBig, Inc., a Delaware corporation ("ScoreBig"), made an assignment for the benefit of its creditors whereby ScoreBig assigned all of its assets to SB (assignment for the benefit of creditors), LLC, a California limited liability company ("SBABC"), established under California law to effectuate the Assignment for the Benefit of Creditors of ScoreBig. SBABC subsequently entered into a License Agreement with a third party ("Licensee"),
- (12) whereby SBABC granted a license of certain of SBABC's intellectual property and general intangibles to Licensee in exchange for certain royalty payments on the future net profits, if any, of Licensee. SBABC, in consideration for the Company's consent to the License Agreement, agreed to pay all payments due under the License Agreement, if any, to the Company until the payment in full in cash of the Company's debt investments in ScoreBig.
- Digital Signal Corporation, a Delaware corporation ("DSC"), made an assignment for the benefit of its creditors whereby DSC assigned all of its assets to DSC (assignment for the benefit of creditors), LLC, a Delaware limited liability company, established under Delaware law to effectuate the Assignment for the Benefit of Creditors of DSC.
- Royalty Agreement received in partial satisfaction of obligations of New Haven Pharmaceuticals, Inc. ("NHP") to the Company in connection with the sale of substantially all of the assets of NHP to Espero Pharmaceuticals, Inc.
- (15) Debt investment has a payment-in-kind ("PIK") feature.

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

December 31, 2016

Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Principal Amount	Cost of Investments (6)	Fair Value
Debt Investments — 133 Debt Investments — Lif Argos Therapeutics, Inc (2)(5)	e Science — 38.5%	(8) Term Loan (9.38% cash (Libor + 8.75%; Floor 9.25%; Ceiling 10.75%), 5.00% ETP, Due	\$4,375	\$ 4,339	\$4,339
		10/1/18) Term Loan (9.38% cash (Libor + 8.75%; Floor 9.25%; Ceiling 10.75%), 5.00% ETP, Due 3/1/19)	5,000	4,969	4,969
New Haven Pharmaceuticals, Inc. (11)	Biotechnology	Term Loan (11.63% cash (Libor + 11.00%; Floor	1,282	1,274	651
		11.50%), 11.42% ETP, Due 3/1/19) Term Loan (11.63% cash (Libor + 11.00%; Floor 11.50%), 11.42% ETP, Due 3/1/19)	427	424	217
		Term Loan (10.63% cash (Libor + 10.00%; Floor	1,973	1,960	1,002
		10.50%), 6.10% ETP, Due 3/1/19) Term Loan (10.13% cash (Libor + 9.50%; Floor 10.00%), 4.00% ETP, Due 4/1/19)	6,185	6,118	3,127
		Term Loan (10.13% cash (Libor + 9.50%; Floor	593	593	303
Palatin Technologies, Inc. (2)(5)	Biotechnology	10.00%), Due 1/31/17) Term Loan (9.13% cash (Libor + 8.50%; Floor 9.00%), 5.00% ETP, Due 1/1/19)	4,000	3,960	3,960
		Term Loan (9.13% cash (Libor + 8.50%; Floor 9.00%), 5.00% ETP, Due 8/1/19)	5,000	4,955	4,955

Sample6, Inc. (2)	Biotechnology	Term Loan (9.63% cash (Libor + 9.00%; Floor	972	969	969
		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) Term Loan (9.63% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)	591	588	588
		Term Loan (9.63% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP,	2,083	2,073	2,073
Strongbridge U.S. Inc. (5)	Biotechnology	Due 4/1/18) Term Loan (8.84% cash (Libor + 8.22%; Floor 8.75%), 8.00% ETP, Due 12/1/20)	7,500	7,353	7,353
vTv Therapeutics Inc. (2)(5)	Biotechnology	Term Loan (10.63% cash (Libor + 10.00%; Floor 10.50%), 6.00% ETP, Due 5/1/20)	6,250	6,106	6,106
Lantos Technologies, Inc. (2)	Medical Device	Term Loan (11.50% cash (Libor + 10.50%; Floor 11.50%), 5.00% ETP, Due 2/1/18)	2,479	2,455	2,320
Mederi Therapeutics, Inc. (2)	Medical Device	Term Loan (12.27% cash (Libor + 11.82%; Floor 12.00%), 4.00% ETP, Due 7/1/17)	1,352	1,344	1,344
		Term Loan (12.27% cash (Libor + 11.82%; Floor 12.00%), 4.00% ETP, Due 7/1/17)	1,352	1,344	1,344
NinePoint Medical, Inc. (2)	Medical Device	Term Loan (9.38% cash (Libor + 8.75%; Floor 9.25%), 4.50% ETP, Due 3/1/19)	4,500	4,461	4,461
		Term Loan (9.38% cash (Libor + 8.75%; Floor 9.25%), 4.50% ETP, Due 3/1/19)	2,250	2,225	2,225
Tryton Medical, Inc. (2)	Medical Device	7.16%), 2.50% ETP, Due 3/1/19) Term Loan (10.66% cash (Prime + 7.16%), 2.50% ETP, Due 3/1/17)	1,313	1,309	1,309
Total Debt Investments – Debt Investments — Tec		,		58,819	53,615
Ekahau, Inc. (2)	Communications	Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)	57	57	57
		Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)	19	19	19
Gwynnie Bee, Inc. (2)	Consumer-related Technologies	Term Loan (11.13% cash (Libor + 10.50%; Floor 11.00%; Ceiling 12.50%), 2.00%	667	657	657
		ETP, Due 11/1/17) Term Loan (11.13% cash (Libor + 10.50%; Floor 11.00%; Ceiling 12.50%), 2.00%	433	424	424
		ETP, Due 2/1/18)	500	492	492

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

		Term Loan (11.13% cash (Libor + 10.50%; Floor 11.00%; Ceiling 12.50%), 2.00% ETP, Due 4/1/18)			
Le Tote, Inc. (2)	Consumer-related Technologies	Term Loan (10.28% cash (Libor + 9.65%; Floor	4,000	3,942	3,942
		10.15%), 5.00% ETP, Due 3/1/20) Term Loan (10.28% cash (Libor + 9.65%; Floor 10.15%), 5.00% ETP, Due 3/1/20)	3,000	2,955	2,955
Rhapsody International, Inc. (2)	Consumer-related Technologies	Term Loan (11.13% cash (Libor + 10.50%; Floor 11.00%), 3.00% ETP, Due 10/1/19)	7,500	7,336	7,336
SavingStar, Inc. (2)	Consumer-related Technologies	Term Loan (11.03% cash (Libor + 10.40%; Floor	2,900	2,860	2,860
		10.90%), 3.00% ETP, Due 6/1/19) Term Loan (11.03% cash (Libor + 10.40%; Floor 10.90%), 3.00% ETP, Due 3/1/20)	2,000	1,965	1,965

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

December 31, 2016

Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Principal Amount	Cost of Investments (6)	Fair Value
MediaBrix, Inc. (2)	Internet and Media	Term Loan (11.63% cash (Libor + 11.00%; Floor	4,000	3,966	3,966
Zinio Holdings, LLC (2)	Internet and Media	11.50%), 3.00% ETP, Due 1/1/20) Term Loan (11.88% cash (Libor + 11.25%; Floor 11.75%), 4.00% ETP, Due 2/1/20)	4,000	3,967	3,967
The NanoSteel Company, Inc. (2)	Materials	Term Loan (10.13% cash (Libor + 9.50%; Floor 10.00%), 5.00% ETP, Due 7/1/19)	5,000	4,940	4,940
		Term Loan (10.13% cash (Libor + 9.50%; Floor	2,500	2,470	2,470
		10.00%), 5.00% ETP, Due 7/1/19) Term Loan (10.13% cash (Libor + 9.50%; Floor 10.00%), 5.00% ETP, Due 1/1/20)	2,500	2,464	2,464
Nanocomp Technologies, Inc. (2)	Networking	Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17)	369	367	367
		Term Loan (11.63% cash (Libor + 11.00%; Floor	3,000	2,939	2,939
Powerhouse Dynamics, Inc. (2)	Power Management	11.50%), 3.00% ETP, Due 4/1/20) Term Loan (11.33% cash (Libor + 10.70%; Floor 11.20%), 3.00% ETP, Due 3/1/19)	2,250	2,220	2,220
Avalanche Technology, Inc. (2)	Semiconductors	Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; Ceiling 11.75%), 2.40% ETP, Due	417	416	416
		4/1/17) Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; Ceiling 11.75%), 2.40% ETP, Due	1,335	1,331	1,331
		10/1/18)	1,548	1,517	1,517

		Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; Ceiling 11.75%), 2.00% ETP, Due 2/1/19)			
Luxtera, Inc. (2)	Semiconductors	Term Loan (10.38% cash (Libor + 9.75%; Floor 10.25%; Ceiling 12.25%), 13.00% ETP, Due 7/1/17)	614	607	607
		Term Loan (10.38% cash (Libor + 9.75%; Floor 10.25%; Ceiling 12.25%), 13.00% ETP, Due 7/1/17)	343	341	341
		Term Loan (9.13% cash (Libor + 8.50%; Floor 9.00%), 4.50% ETP, Due 12/1/18)	667	663	663
		Term Loan (9.13% cash (Libor + 8.50%; Floor 9.00%), 4.50% ETP, Due 12/1/18)	667	663	663
		Term Loan (9.63% cash (Libor + 9.00%; Floor 9.50%), 4.50% ETP, Due 11/1/19)	2,000	1,990	1,990
Xtera Communications, Inc. (5)(11)	Semiconductors	Term Loan (12.50% cash, 22.92% ETP, Due 11/1/16)	3,056	3,047	_
		Term Loan (12.50% cash, 22.92% ETP, Due 11/1/16)	936	933	_
Bridge2 Solutions, Inc.	Software	Term Loan (11.63% cash (Libor + 11.00%; Floor 11.50%; Ceiling 14.50%), 2.00% ETP,	4,000	3,976	3,976
		Due 7/1/19) Term Loan (11.63% cash (Libor + 11.00%; Floor 11.50%; Ceiling 14.50%), 2.00% ETP,	1,000	996	996
ControlScan, Inc. (2)	Software	Due 1/1/20) Term Loan (10.88% cash (Libor + 10.25%), 3.00% ETP, Due 7/1/20)	4,500	4,413	4,413
Decisyon, Inc.	Software	Term Loan (12.94% cash (Libor + 12.308%; Floor 12.50%), 6.50% ETP, Due 6/1/18)	1,523	1,521	1,519
		Term Loan (12.94% cash (Libor + 12.308%; Floor 12.50%), 6.50% ETP, Due 6/1/18)	833	715	713
Digital Signal Corporation (11)(13)	Software	Term Loan (10.88% cash (Libor + 10.25%; Floor	1,280	1,246	